|
1
|
Brennan FM and McInnes IB: Evidence that
cytokines play a role in rheumatoid arthritis. J Clin Invest.
118:3537–3545. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Ungethuem U, Haeupl T, Witt H, Koczan D,
Krenn V, Huber H, von Helversen TM, Drungowski M, Seyfert C, Zacher
J, et al: Molecular signatures and new candidates to target the
pathogenesis of rheumatoid arthritis. Physiol Genomics.
42A:267–282. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nixon R, Bansback N and Brennan A: The
efficacy of inhibiting tumour necrosis factor alpha and interleukin
1 in patients with rheumatoid arthritis: A meta-analysis and
adjusted indirect comparisons. Rheumatology (Oxford). 46:1140–1147.
2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Verhoef LM, van den Bemt BJ, van der Maas
A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, Jacobs WC, van
Herwaarden N and den Broeder AA: Down-titration and discontinuation
strategies of tumour necrosis factor-blocking agents for rheumatoid
arthritis in patients with low disease activity. Cochrane Database
Syst Rev. 5(CD010455)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Upchurch KS and Kay J: Evolution of
treatment for rheumatoid arthritis. Rheumatology (Oxford).
51:vi28–vi36. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Quan LD, Thiele GM, Tian J and Wang D: The
development of novel therapies for rheumatoid arthritis. Expert
Opin Ther Pat. 18:723–738. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
O'Dell JR: Therapeutic strategies for
rheumatoid arthritis. N Engl J Med. 350:2591–2602. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mori S: Management of rheumatoid arthritis
patients with interstitial lung disease: Safety of biological
antirheumatic drugs and assessment of pulmonary fibrosis. Clin Med
Insights Circ Respir Pulm Med. 9 (Suppl 1):S41–S49. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Klarenbeek NB, Güler-Yüksel M, van der
Kooij SM, Han KH, Ronday HK, Kerstens PJ, Seys PE, Huizinga TW,
Dijkmans BA and Allaart CF: The impact of four dynamic,
goal-steered treatment strategies on the 5-year outcomes of
rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis.
70:1039–1046. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Inui K and Koike T: Combination therapy
with biologic agents in rheumatic diseases: Current and future
prospects. Ther Adv Musculoskelet Dis. 8:192–202. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bruce TO: Comorbid depression in
rheumatoid arthritis: Pathophysiology and clinical implications.
Curr Psychiatry Rep. 10:258–264. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jacob L, Rockel T and Kostev K: Depression
risk in patients with rheumatoid arthritis in the United Kingdom.
Rheumatol Ther. 4:195–200. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Margaretten M, Julian L, Katz P and Yelin
E: Depression in patients with rheumatoid arthritis: Description,
causes and mechanisms. Int J Clin Rheumtol. 6:617–623.
2011.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Schiepers OJ, Wichers MC and Maes M:
Cytokines and major depression. Prog Neuropsychopharmacol Biol
Psychiatry. 29:201–217. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Viatte S, Plant D and Raychaudhuri S:
Genetics and epigenetics of rheumatoid arthritis. Nat Rev
Rheumatol. 9:141–153. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
McInnes IB and Schett G: Cytokines in the
pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 7:429–442.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Firestein GS: Evolving concepts of
rheumatoid arthritis. Nature. 423:356–361. 2003.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kinne RW, Stuhlmüller B and Burmester GR:
Cells of the synovium in rheumatoid arthritis. Macrophages.
Arthritis Res Ther. 9(224)2007.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Kinne RW, Bräuer R, Stuhlmüller B,
Palombo-Kinne E and Burmester GR: Macrophages in rheumatoid
arthritis. Arthritis Res. 2:189–202. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Hata H, Sakaguchi N, Yoshitomi H, Iwakura
Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T
and Sakaguchi S: Distinct contribution of IL-6, TNF-alpha, IL-1,
and IL-10 to T cell-mediated spontaneous autoimmune arthritis in
mice. J Clin Invest. 114:582–588. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Schett G and Gravallese E: Bone erosion in
rheumatoid arthritis: Mechanisms, diagnosis and treatment. Nat Rev
Rheumatol. 8:656–664. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Silveira KD, Coelho FM, Vieira AT, Barroso
LC, Queiroz-Junior CM, Costa VV, Sousa LF, Oliveira ML, Bader M,
Silva TA, et al: Mechanisms of the anti-inflammatory actions of the
angiotensin type 1 receptor antagonist losartan in experimental
models of arthritis. Peptides. 46:53–63. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ruscitti P, Cipriani P, Liakouli V,
Carubbi F, Berardicurti O, Di Benedetto P, Ciccia F, Guggino G,
Alvaro S, Triolo G and Giacomelli R: The emerging role of IL-1
inhibition in patients affected by rheumatoid arthritis and
diabetes. Rev Recent Clin Trials. 13:210–214. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zou Y, Zeng S, Huang M, Qiu Q, Xiao Y, Shi
M, Zhan Z, Liang L, Yang X and Xu H: Inhibition of
6-phosphofructo-2-kinase suppresses fibroblast-like
synoviocytes-mediated synovial inflammation and joint destruction
in rheumatoid arthritis. Br J Pharmacol. 174:893–908.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Buckley CD: Michael Mason prize essay
2003. Why do leucocytes accumulate within chronically inflamed
joints? Rheumatology (Oxford). 42:1433–1444. 2003.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kay J and Calabrese L: The role of
interleukin-1 in the pathogenesis of rheumatoid arthritis.
Rheumatology (Oxford). 43 (Suppl 3):iii2–iii9. 2004.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Arend WP, Palmer G and Gabay C: IL-1,
IL-18, and IL-33 families of cytokines. Immunol Rev. 223:20–38.
2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nakae S, Saijo S, Horai R, Sudo K, Mori S
and Iwakura Y: IL-17 production from activated T cells is required
for the spontaneous development of destructive arthritis in mice
deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA.
100:5986–5990. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Abramson SB and Amin A: Blocking the
effects of IL-1 in rheumatoid arthritis protects bone and
cartilage. Rheumatology (Oxford). 41:972–980. 2002.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jacques C, Gosset M, Berenbaum F and Gabay
C: The role of IL-1 and IL-1Ra in joint inflammation and cartilage
degradation. Vitam Horm. 74:371–403. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lebre MC, Jongbloed SL, Tas SW, Smeets TJ,
McInnes IB and Tak PP: Rheumatoid arthritis synovium contains two
subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine
profiles. Am J Pathol. 172:940–950. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Plater-Zyberk C, Joosten LA, Helsen MM,
Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P,
Aloni S, Cirillo R, et al: Therapeutic effect of neutralizing
endogenous IL-18 activity in the collagen-induced model of
arthritis. J Clin Invest. 108:1825–1832. 2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lotz M: The role of nitric oxide in
articular cartilage damage. Rheum Dis Clin North Am. 25:269–282.
1999.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tanaka T, Narazaki M and Kishimoto T: IL-6
in inflammation, immunity, and disease. Cold Spring Harb Perspect
Biol. 6(a016295)2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Alonzi T, Fattori E, Lazzaro D, Costa P,
Probert L, Kollias G, De Benedetti F, Poli V and Ciliberto G:
Interleukin 6 is required for the development of collagen-induced
arthritis. J Exp Med. 187:461–468. 1998.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kishimoto T: Interleukin-6: From basic
science to medicine-40 years in immunology. Annu Rev Immunol.
23:1–21. 2005.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Narazaki M, Tanaka T and Kishimoto T: The
role and therapeutic targeting of IL-6 in rheumatoid arthritis.
Expert Rev Clin Immunol. 13:535–551. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Marrelli A, Cipriani P, Liakouli V,
Carubbi F, Perricone C, Perricone R and Giacomelli R: Angiogenesis
in rheumatoid arthritis: A disease specific process or a common
response to chronic inflammation? Autoimmun Rev. 10:595–598.
2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Johnson KE and Wilgus TA: Vascular
endothelial growth factor and angiogenesis in the regulation of
cutaneous wound repair. Adv Wound Care (New Rochelle). 3:647–661.
2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sokolove J and Lepus CM: Role of
inflammation in the pathogenesis of osteoarthritis: Latest findings
and interpretations. Ther Adv Musculoskelet Dis. 5:77–94.
2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Diaz-Torne C, Ortiz MDA, Moya P, Hernandez
MV, Reina D, Castellvi I, De Agustin JJ, Fuente D, Corominas H,
Sanmarti R, et al: The combination of IL-6 and its soluble receptor
is associated with the response of rheumatoid arthritis patients to
tocilizumab. Semin Arthritis Rheum. 47:757–764. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Aggarwal BB: Signalling pathways of the
TNF superfamily: A double-edged sword. Nat Rev Immunol. 3:745–756.
2003.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Holnthoner W, Bonstingl C, Hromada C,
Muehleder S, Zipperle J, Stojkovic S, Redl H, Wojta J, Schöchl H,
Grillari J, et al: Endothelial cell-derived extracellular vesicles
size-dependently exert procoagulant activity detected by
thromboelastometry. Sci Rep. 7(3707)2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Horiuchi T, Mitoma H, Harashima S,
Tsukamoto H and Shimoda T: Transmembrane TNF-alpha: Structure,
function and interaction with anti-TNF agents. Rheumatology
(Oxford). 49:1215–1228. 2010.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chen X and Oppenheim JJ: Contrasting
effects of TNF and anti-TNF on the activation of effector T cells
and regulatory T cells in autoimmunity. FEBS Lett. 585:3611–3618.
2011.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Yamagishi S, Ohnishi M and Pawankar R:
IL-1 and TNF-alpha-mediated regulation of IL-6, IL-8, and GM-CSF
release from cultured nasal epithelial cells. Nihon Jibiinkoka
Gakkai Kaiho. 103:829–835. 2000.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
47
|
Fiocco U, Sfriso P, Oliviero F, Lunardi F,
Calabrese F, Scagliori E, Cozzi L, Di Maggio A, Nardacchione R,
Molena B, et al: Blockade of intra-articular TNF in peripheral
spondyloarthritis: Its relevance to clinical scores, quantitative
imaging and synovial fluid and synovial tissue biomarkers. Joint
Bone Spine. 80:165–170. 2013.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Bevaart L, Vervoordeldonk MJ and Tak PP:
Evaluation of therapeutic targets in animal models of arthritis:
How does it relate to rheumatoid arthritis? Arthritis Rheum.
62:2192–2205. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Monach PA, Benoist C and Mathis D: The
role of antibodies in mouse models of rheumatoid arthritis, and
relevance to human disease. Adv Immunol. 82:217–248.
2004.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hassan S, Milman U, Feld J, Eder L, Lavi
I, Cohen S and Zisman D: Effects of anti-TNF-α treatment on lipid
profile in rheumatic diseases: An analytical cohort study.
Arthritis Res Ther. 18(261)2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ma X and Xu S: TNF inhibitor therapy for
rheumatoid arthritis. Biomed Rep. 1:177–184. 2013.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Bourne T, Fossati G and Nesbitt A: A
PEGylated Fab' fragment against tumor necrosis factor for the
treatment of Crohn disease: Exploring a new mechanism of action.
BioDrugs. 22:331–337. 2008.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Capria A, De Nardo D, Baffetti FR, Barbini
U, Violo A, Tondo T and Fontana L: Long-term anti-TNF-alpha
treatments reverse the endothelial dysfunction in rheumatoid
arthritis: The biological coherence between synovial and
endothelial inflammation. Int J Immunopathol Pharmacol. 23:255–262.
2010.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Tam LS, Kitas GD and Gonzalez-Gay MA: Can
suppression of inflammation by anti-TNF prevent progression of
subclinical atherosclerosis in inflammatory arthritis? Rheumatology
(Oxford). 53:1108–1119. 2014.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Moelants EA, Mortier A, Van Damme J and
Proost P: Regulation of TNF-α with a focus on rheumatoid arthritis.
Immunol Cell Biol. 91:393–401. 2013.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Lis K, Kuzawińska O and Balkowiec-Iskra E:
Tumor necrosis factor inhibitors-state of knowledge. Arch Med Sci.
10:1175–1185. 2014.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Radner H and Aletaha D: Anti-TNF in
rheumatoid arthritis: An overview. Wien Med Wochenschr. 165:3–9.
2015.PubMed/NCBI View Article : Google Scholar
|
|
58
|
van Schouwenburg PA, Rispens T and Wolbink
GJ: Immunogenicity of anti-TNF biologic therapies for rheumatoid
arthritis. Nat Rev Rheumatol. 9:164–172. 2013.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Dommasch E and Gelfand JM: Is there truly
a risk of lymphoma from biologic therapies? Dermatol Ther.
22:418–430. 2009.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Wolfe F and Michaud K: Biologic treatment
of rheumatoid arthritis and the risk of malignancy: Analyses from a
large US observational study. Arthritis Rheum. 56:2886–2895.
2007.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Bullock J, Rizvi SAA, Saleh AM, Ahmed SS,
Do DP, Ansari RA and Ahmed J: Rheumatoid arthritis: A brief
overview of the treatment. Med Princ Pract. 27:501–507.
2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Kalliolias GD and Liossis SN: The future
of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis
to adult-onset Still's disease and systemic-onset juvenile
idiopathic arthritis. Expert Opin Investig Drugs. 17:349–359.
2008.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Ramírez J and Cañete JD: Anakinra for the
treatment of rheumatoid arthritis: A safety evaluation. Expert Opin
Drug Saf. 17:727–732. 2018.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Bresnihan B, Newmark R, Robbins S and
Genant HK: Effects of anakinra monotherapy on joint damage in
patients with rheumatoid arthritis. Extension of a 24-week
randomized, placebo-controlled trial. J Rheumatol. 31:1103–1111.
2004.PubMed/NCBI
|
|
65
|
Araki M, Matsuoka T, Miyamoto K, Kusunoki
S, Okamoto T, Murata M, Miyake S, Aranami T and Yamamura T:
Efficacy of the anti-IL-6 receptor antibody tocilizumab in
neuromyelitis optica: A pilot study. Neurology. 82:1302–1306.
2014.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Scott LJ: Tocilizumab: A review in
rheumatoid arthritis. Drugs. 77:1865–1879. 2017.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Smolen JS, Beaulieu A, Rubbert-Roth A,
Ramos-Remus C, Rovensky J, Alecock E, Woodworth T and Alten R:
OPTION Investigators. Effect of interleukin-6 receptor inhibition
with tocilizumab in patients with rheumatoid arthritis (OPTION
study): A double-blind, placebo controlled, randomised trial.
Lancet. 371:987–997. 2008.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Maini RN, Taylor PC, Szechinski J, Pavelka
K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, et
al: Double-blind randomized controlled clinical trial of the
interleukin-6 receptor antagonist, tocilizumab, in European
patients with rheumatoid arthritis who had an incomplete response
to methotrexate. Arthritis Rheum. 54:2817–2829. 2006.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Yip RML and Yim CW: Role of interleukin-6
inhibitors in the management of rheumatoid arthritis. J Clin
Rheumatol:. 2019, doi: 10.1097/RHU.0000000000001293 (Online ahead
of print).
|
|
70
|
Park JY and Pillinger MH: Interleukin-6 in
the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 65
(Suppl 1):S4–S10. 2007.PubMed/NCBI
|
|
71
|
Conigliaro P, Triggianese P, De Martino E,
Fonti GL, Chimenti MS, Sunzini F, Viola A, Canofari C and Perricone
R: Challenges in the treatment of rheumatoid arthritis. Autoimmun
Rev. 18:706–713. 2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Emery P, Pope JE, Kruger K, Lippe R,
DeMasi R, Lula S and Kola B: Efficacy of monotherapy with biologics
and JAK inhibitors for the treatment of rheumatoid arthritis: A
systematic review. Adv Ther. 35:1535–1563. 2018.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Gaffen SL: The role of interleukin-17 in
the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep.
11:365–370. 2009.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Kasperkovitz PV, Verbeet NL, Smeets TJ,
van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP and
Verweij CL: Activation of the STAT1 pathway in rheumatoid
arthritis. Ann Rheum Dis. 63:233–239. 2004.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Hodes GE, Ménard C and Russo SJ:
Integrating Interleukin-6 into depression diagnosis and treatment.
Neurobiol Stress. 4:15–22. 2016.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Khandaker GM, Pearson RM, Zammit S, Lewis
G and Jones PB: Association of serum interleukin 6 and C-reactive
protein in childhood with depression and psychosis in young adult
life: A population-based longitudinal study. JAMA Psychiatry.
71:1121–1128. 2014.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Koo JW and Duman RS: Evidence for IL-1
receptor blockade as a therapeutic strategy for the treatment of
depression. Curr Opin Investig Drugs. 10:664–671. 2009.PubMed/NCBI
|
|
78
|
Raison CL, Capuron L and Miller AH:
Cytokines sing the blues: Inflammation and the pathogenesis of
depression. Trends Immunol. 27:24–31. 2006.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Steptoe A, Hamer M and Chida Y: The
effects of acute psychological stress on circulating inflammatory
factors in humans: A review and meta-analysis. Brain Behav Immun.
21:901–912. 2007.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Liu H, Luiten PG, Eisel UL, Dejongste MJ
and Schoemaker RG: Depression after myocardial infarction:
TNF-α-induced alterations of the blood-brain barrier and its
putative therapeutic implications. Neurosci Biobehav Rev.
37:561–572. 2013.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Abbott R, Whear R, Nikolaou V, Bethel A,
Coon JT, Stein K and Dickens C: Tumour necrosis factor-α inhibitor
therapy in chronic physical illness: A systematic review and
meta-analysis of the effect on depression and anxiety. J Psychosom
Res. 79:175–184. 2015.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Kamel KM, Gad AM, Mansour SM, Safar MM and
Fawzy HM: Venlafaxine alleviates complete Freund's adjuvant-induced
arthritis in rats: Modulation of STAT-3/IL-17/RANKL axis. Life Sci.
226:68–76. 2019.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Song L, Quan X, Su L, Wang K, Wang H, Wu
L, Chen C, Li S, Xiang W, Chen L and Zhou J: Inflammation and
behavioral symptoms in preoperational glioma patients: Is
depression, anxiety, and cognitive impairment related to markers of
systemic inflammation? Brain Behav. 10(e01771)2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Lu DY, Leung YM and Su LP: Interferon-α
induces nitric oxide synthase expression and haem oxygenase-1
down-regulation in microglia: Implications of cellular mechanism of
IFN-α-induced depression. Int J Neuropsychopharmacol. 16:433–444.
2013.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Carboni l, McCarthy DJ, Delafont B, Filosi
M, Ivanchenko E, Ratti E, Learned SM, Alexander R and Domenici E:
Biomarkers for response in major depression: Comparing paroxetine
and venlafaxine from two randomised placebo-controlled clinical
studies. Transl Psychiatry. 9(182)2019.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Simen BB, Duman CH, Simen AA and Duman RS:
TNFalpha signaling in depression and anxiety: Behavioral
consequences of individual receptor targeting. Biol Psychiatry.
59:775–785. 2006.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Telfer JF and Brock JH: Proinflammatory
cytokines increase iron uptake into human monocytes and synovial
fibroblasts from patients with rheumatoid arthritis. Med Sci Monit.
10:BR91–BR95. 2004.PubMed/NCBI
|
|
88
|
Jenkins JK, Hardy KJ and McMurray RW: The
pathogenesis of rheumatoid arthritis: A guide to therapy. Am J Med
Sci. 323:171–180. 2002.PubMed/NCBI View Article : Google Scholar
|
|
89
|
De Simone V, Franzè E, Ronchetti G,
Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald
TT, Pallone F, et al: Th17-type cytokines, IL-6 and TNF-α
synergistically activate STAT3 and NF-kB to promote colorectal
cancer cell growth. Oncogene. 34:3493–3503. 2015.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Kato H, Endres J and Fox DA: The roles of
IFN-γ versus IL-17 in pathogenic effects of human Th17 cells on
synovial fibroblasts. Mod Rheumatol. 23:1140–1150. 2013.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Campbell J, Ciesielski CJ, Hunt AE,
Horwood NJ, Beech JT, Hayes LA, Denys A, Feldmann M, Brennan FM and
Foxwell BM: A novel mechanism for TNF-alpha regulation by p38 MAPK:
Involvement of NF-kappa B with implications for therapy in
rheumatoid arthritis. J Immunol. 173:6928–6937. 2004.PubMed/NCBI View Article : Google Scholar
|
|
92
|
De Cesaris P, Starace D, Riccioli A,
Padula F, Filippini A and Ziparo E: Tumor necrosis factor-alpha
induces interleukin-6 production and integrin ligand expression by
distinct transduction pathways. J Biol Chem. 273:7566–5671.
1998.PubMed/NCBI View Article : Google Scholar
|
